<DOC>
	<DOCNO>NCT01370980</DOCNO>
	<brief_summary>The purpose study implement support interdisciplinary program ( oncologist , pharmacist , physician , nurse , league cancer ) medication adherence oral oncology treatment . The aim ensure continuity care professional , effectiveness treatment patient safety .</brief_summary>
	<brief_title>Collaborative Seamless Care Oncology : Measure Reinforce Safety Adherence Oral Cancer Treatment</brief_title>
	<detailed_description>80 patient include swiss-romande hospital private oncologist follow thirty study pharmacy . Each refusal drop-out document . Follow-up duration 48 week , motivational interviewing least every three month . Patient adherence assess electronically MEMS ( Medication Event Monitoring System ) .</detailed_description>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>18 year older Treated cancer oral medication ( letrozol , exemestan , imatinib , sunitinib , nilotinib , everolimus , deferasirox ) French speak None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Medication Adherence</keyword>
	<keyword>Patient Compliance</keyword>
	<keyword>Patient Acceptance Health Care</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Cancer</keyword>
	<keyword>Letrozol</keyword>
	<keyword>Exemestan</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Deferasirox</keyword>
</DOC>